Leiden University Scholarly Publications

Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy

A nomogram to predict severe toxicity in DPYD wild-type patients treated with capecitabine-based anticancer regimens

Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters"

Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters"

Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil

Transtympanic sodium thiosulfate for prevention of cisplatin-induced ototoxicity

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? reply

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens

An LC-MS/MS method for quantification of the active abiraterone metabolite Delta(4)-abiraterone (D4A) in human plasma

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman

Letter regarding Zhao et al. entitled "DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia"